Hepatitis C, Chronic Clinical Trial
Official title:
Reengaging Patients With Previously Diagnosed Hepatitis C in to Care
Aims:
To evaluate the impact of a letter, phone call and incentive in re-engaging patients with
hepatitis C care.
Outcomes of interest:
Primary outcome of interest:
- Attendance for assessment of liver disease within 4 months of being sent invitation letter.
Secondary outcomes of interest:
- Commencing treatment within 6 months of being sent invitation letter.
Methods:
Patient identification:
The local copy of the Scottish Hepatitis C database holds data regarding patients referred to
secondary care for treatment of their hepatitis C, and holds ethics approval for research on
treatment and patient outcomes. This will be used to identify patients with hepatitis C
infection that is untreated, treatment has been unsuccessful, or the patient has been treated
but the outcome is unknown (due to non attendance for blood tests). The database has been
cross checked with virus lab results, to ensure infection status is up to date. Finally, the
patient data has been checked by NHS GG&C information team, to exclude patients who are
deceased, or whom are no longer resident in NHS greater Glasgow and Clyde based on updated
details obtained from SCIstore.
Inclusion criteria:
Patients (16 years and over) who have previously engaged with Hepatitis C services in Glasgow
but who are either untreated, have been treated unsuccessfully, or have been treated but have
not attended for blood tests to check for treatment success.
Exclusion criteria:
Patients with HIV. Patients no longer resident within NHS Greater Glasgow and Clyde area.
Allocation to contact groups:
Patients will be randomly distributed into 3 groups:
1. Letter: Will be sent letter 1 (appendix)
2. Letter plus telephone call: will be sent letter 2 (appendix) and be followed up with a
telephone call from the treatment centre if no contact has been received after 4 weeks
3. Letter plus incentive: will be sent letter 3 (appendix)
Process:
Patient letters will be sent out by GG&C public health. For all 3 groups the letter will be
sent with the small Hepatitis C Scotland booklet "Hepatitis C treatments have changed".
Letters will identify include the telephone number for the identified treatment centre which
will be either, the last known treatment centre or a more local treatment centre were
appropriate based on current residence.
Primary and secondary outcomes measures will be collected via the Scottish Hepatitis C
database.
Lay Summary:
This study will test whether a letter alone, a letter plus follow up phone call or a letter
with offer of incentive, will be most effective in re-engaging patients who are known to have
hepatitis C but not yet received treatment.
n/a
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03413696 -
Effects of Health Literacy and HCV Knowledge on HCV Treatment Willingness in HIV-coinfected Patients
|
||
Completed |
NCT03740906 -
Direct-acting Antiviral Therapy and Reinfection Among People With Chronic Hepatitis C Virus Infection and Recent Injecting Drug Use in the Prison Setting
|
||
Terminated |
NCT02465203 -
3-year Follow-up Study to Assess the Viral Activity in Hepatitis C Patients Who Failed Feeder DEB025/Alisporivir Study
|
Phase 3 | |
Completed |
NCT02262728 -
An Efficacy, Safety and Pharmacokinetics Study of Simeprevir, Daclatasvir and Sofosbuvir in Participants With Chronic Hepatitis C Virus Genotype 1 or 4 Infection and Decompensated Liver Disease
|
Phase 2 | |
Completed |
NCT01429792 -
A Study Evaluating Slow Response/Non-Rapid Response in Patients With Chronic Hepatitis C, Genotype 1, 2, 3 & 4 Treated With Pegasys (Peginterferon Alfa-2a) and Copegus (Ribavirin)
|
Phase 4 | |
Completed |
NCT02541409 -
Directly Observed Therapy for HCV in Chennai, India
|
Phase 2 | |
Completed |
NCT01846832 -
A Study of TMC435 Plus Pegylated Interferon Alfa-2a and Ribavirin in Participants With Chronic HCV Infection
|
Phase 3 | |
Withdrawn |
NCT01608737 -
A Phase III Study of BI201335 in Treatment-naive and Prior Relapser Patients With Chronic Hepatitis C Infection
|
Phase 3 | |
Completed |
NCT01435226 -
GS-5885, GS-9451, Tegobuvir and Ribovirin in Treatment-Experienced Subjects With Chronic Genotype 1a Or 1b Hepatitis C Virus (HCV) Infection
|
Phase 2 | |
Completed |
NCT01447446 -
An Observational Study on Dual And Triple Therapies Based on Peginterferon Alfa (e.g. Pegasys) in Patients With Chronic Hepatitis C
|
N/A | |
Completed |
NCT01435044 -
Safety Study of Regimens of Sofosbuvir, GS-0938, and Ribavirin in Patients With Chronic Hepatitis C Infection
|
Phase 2 | |
Completed |
NCT01399619 -
Phase III Trial of BI 201335 (Faldaprevir) in Treatment Naive (TN) and Relapser Hepatitis C Virus (HCV)-Human Immunodeficiency Virus (HIV) Coinfected Patients (STARTverso 4)
|
Phase 3 | |
Completed |
NCT02113631 -
Comparative Effectiveness and Tolerability of Boceprevir vs Telaprevir
|
N/A | |
Terminated |
NCT01168856 -
An Observational Study on Long-Term Persistence of Resistant Mutations And Durability of Sustained Virological Response in Patients With Chronic Hepatitis C Treated With Direct Acting Antiviral (DAA)- Containing Regimens
|
N/A | |
Completed |
NCT00725751 -
Treatment of Chronic Hepatitis C With Pegylated Interferon and Ribavirin in Participants With/Without Substitution Therapy (P05255)
|
N/A | |
Completed |
NCT00793793 -
Safety, Antiviral Activity and PK of MRD of BI 201335 in Chronic Hepatitis C Patients Both Treatment Naive and -Experienced
|
Phase 1 | |
Completed |
NCT00377182 -
A Study of Hepatitis C Virus (HCV) Polymerase Inhibitor Pro-Drug in Combination With PEGASYS With or Without COPEGUS in Patients With Chronic Hepatitis C (CHC) Genotype 1 Infection.
|
Phase 2 | |
Completed |
NCT00375661 -
Low-dose Peg-interferon Plus Ribavirin (IFN/RBV) for Prevention of Hepatocellular Carcinoma (HCC) Recurrence in Patients Who Had Surgery to Remove Primary HCC
|
Phase 4 | |
Completed |
NCT00217139 -
A Study to Evaluate the Safety and Efficacy of Celgosivir and Peginterferon Alfa-2b, With or Without Ribavirin, in Patients With Chronic Hepatitis C Genotype 1 Infection
|
Phase 2 | |
Completed |
NCT00723632 -
Pharmacoeconomic Study Assessing the Cost of Chronic Hepatitis C Treatment With Peginterferon Alfa-2b (PegIntron) and Ribavirin (Rebetol) in the Czech Republic (Study P04588)(COMPLETED)
|
N/A |